Key features and details | |
Cat. No. | MABL-3092 |
Name | Anti-Tissue factor mAbs |
Clone No. | AFD-1157 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | ELISA, FC |
Species Reactivity | Mouse |
Basic Information | |
Specificity | This antibody binds mouse tissue factor (mTF) between amino acids 30 to 251. mTF hemostatic protein which is involved in the extrinsic pathway of coagulation. TF is receptor for circulating serine protease factor VIIa, activating the catalytic VIIa protease domain. The complex formed functions to activate the zymogen factor X into activated factor Xa, which then catalyzes the formation of Prothrombin to Thrombin. The pathways results in a fibrin clot which acts to stop bleeding. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade. |
Alternative Name | CD142; TF; mTF; F3; Coagulation factor III; Thromboplastin; platelet tissue factor; factor III |
UniProt | P20352 |
Immunogen | The original antibody was generated by immunizing 6-week-old Wistar female rats intraperitoneally with recombinant mouse tissue factor protein comprising amino acid sequence between 30 to 251 in Freund's complete adjuvant. |
Application Notes | The initial binding characterization of the hybridoma supernatant for mouse tissue factor was done using ELISA. The binding was further confirmed with flow cytometry by measuring the reactivity of the hybridoma culture supernatant to mTF-expressing cells. This antibody was capable of being internalized by TF-forced-expression mouse B16 melanoma cells expressing mTF (US9920133). |
Antibody First Published | |
Note on publication | |
COA Information (For reference only, actual COA shall prevail) | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |